Torrent Pharma Launches Semaglutide Brands Sembolic and Semalix in India
Torrent Pharma launched Semaglutide brands Sembolic (oral) and Semalix (injectable) in India on March 21, 2026. This marks the company's entry into the GLP-1 therapy segment for type-2 diabetes and obesity. Semalix injectable is priced at ₹3,999 per month. Torrent Pharma is the first Indian company to offer generic oral semaglutide.
The launch of Semaglutide formulations addresses a significant healthcare challenge in India and expands Torrent Pharma's presence in the metabolic disorders segment, potentially impacting future revenue growth. However, the full impact will depend on market adoption and competition.
The launch of new drug formulations, especially in a significant therapeutic area like metabolic disorders, and being the first in India to offer oral generic semaglutide, is a positive development for the company.
Torrent Pharmaceuticals announced the launch of its Semaglutide brands, Sembolic (oral) and Semalix (injectable), in India on March 21, 2026. This move expands the company's portfolio in treating metabolic disorders like type-2 diabetes and obesity.
Amal Kelshikar, CEO – India Business at Torrent Pharma, stated that the company's entry into the GLP-1 therapy segment underscores its commitment to providing affordable treatment options for complex metabolic conditions. Torrent Pharma is the first Indian company to offer Semaglutide in both oral and injectable formulations.
The GLP-1 receptor agonists, like Semaglutide, are prescription medications used for managing type 2 diabetes and obesity. They function by boosting insulin secretion, reducing glucagon levels, and aiding appetite regulation, thereby improving HbA1c levels, promoting weight loss, and potentially reducing cardiovascular event risk.
Torrent Pharma, the flagship company of the Torrent Group, has annual revenues exceeding ₹11,500 crore. Following the JB Pharma acquisition, it ranks 5th in the Indian Pharmaceuticals Market and is a top 5 player in Cardiovascular, Gastro Intestinal, Central Nervous System, Pain Management, and Cosmo-Dermatology segments. The company has a presence in over 50 countries and is a leading Indian pharma company in Brazil and Germany. Torrent operates 8 manufacturing facilities, 5 of which are USFDA approved, and employs over 750 scientists in its R&D division.
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.